| Literature DB >> 22749946 |
Víctor Echeverry-Alzate1, María Tuda-Arízcun, Kora-Mareen Bühler, Ángel Santos, Elena Giné, Pedro Olmos, Miguel Ángel Gorriti, Evelio Huertas, Fernando Rodríguez de Fonseca, Jose Antonio López-Moreno.
Abstract
Naltrexone is a clinically approved medication for alcoholism. We aimed to investigate the effectiveness of naltrexone co-administered with cocaine and the association of these substances with immediate-early gene expression in the rat prefrontal cortex. We used chronic operant ethanol self-administration and oral treatments prescribed for alcoholism and available in pharmacies to maximise the predictive validity in humans. We performed real-time PCR analysis to determine gene expression levels in the prefrontal cortex. Only the highest dose of naltrexone (1, 3, and 10 mg/kg, p.o.) reduced the response to ethanol. Cocaine increased ethanol self-administration in a dose-dependent manner (2.5, 10, 20 mg/kg, i.p.) and reversed the naltrexone-induced reduction. Naltrexone failed to prevent the cocaine-induced increase in locomotor activity observed in these animals. Chronic self-administration of ethanol reduced the expression of the C-fos gene 4- to 12-fold and increased expression of the COX-2 (up to 4-fold) and Homer1a genes in the rat prefrontal cortex. Chronic ethanol self-administration is prevented by naltrexone, but cocaine fully reverses this effect. This result suggests that cocaine may overcome naltrexone's effectiveness as a treatment for alcoholism. The ethanol-induced reduction in C-fos gene expression in the prefrontal cortex reveals an abnormal activity of these neurons, which may be relevant in the compulsive consumption of ethanol, the control of reward-related areas and the behavioural phenotype of ethanol addiction.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22749946 DOI: 10.1016/j.neuropharm.2012.06.010
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250